Health Care Update: Market Insights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 20 2025
0mins
Should l Buy ?
Source: WSJ
Novartis Midterm Outlook: Novartis has provided a midterm outlook that exceeds expectations, with potential for raised forecasts due to the company's strong track record of meeting commitments.
Impact of Patent Expiration: The new outlook extends to the 2025-30 period, coinciding with the patent expiration of the psoriasis drug Cosentyx.
Increased Sales Guidance: The company has raised its peak sales guidance for key drugs, including breast-cancer treatment Kisqali and leukemia drug Scemblix.
Stock Performance: Following the announcement, Novartis shares experienced a slight increase of 0.6%, reaching 102.86 Swiss francs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
